End-stage Renal Disease Market – Growth, Trends, COVID-19 Impact, and Forecast(2022 - 2027)

The End-stage Renal Disease Market is Segmented by Treatment (Kidney Transplantation and Dialysis), Diagnosis (Blood Test, Urine Test, Imaging Test, and Other Diagnoses), and Geography (North America, Europe, Asia-Pacific, Middle East, Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

End Stage renal Disease market 2
Study Period: 2018-2025
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 10 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The end-stage renal disease market is expected to witness a CAGR of around 10% during the forecast period.

The current coronavirus disease 2019 (COVID-19) pandemic is forcing unprecedented changes in daily life people. Many patients are under lockdown during this time, and the nephrology community has been forced to adapt quickly to this new reality. Patients on dialysis are at high risk of COVID-19 exposure due to the widespread use of public transportation and densely packed clinical spaces. Under the 2018 Bipartisan Budget Act, the Centers for Medicare & Medicaid Services (CMS) allowed patients on home dialysis to choose to have their monthly end-stage renal disease (ESKD) clinical assessments through telehealth, resulting in an increased demand for home dialysis, worldwide. According to a report published in April 2020, the Rogosin Institute, an independent dialysis provider affiliated with New York-Presbyterian Hospital with a home dialysis population of 210 patients, out of which 150 were on peritoneal dialysis (PD) and 60 on home hemodialysis (HHD). COVID-19 has a major impact on the kidney of the patients. According to the National Kidney Foundation, in April 2020, 37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% in hospitalized COVID-19 patients.

The end-stage renal disease market is driven by the increasing number of patients suffering from chronic kidney disease. According to the National Kidney Foundation, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. The rate of patients with chronic kidney disease is increasing. According to the report published in The Lancet Journal in February 2020, over 40% of people required dialysis with severe chronic kidney disease.

Another factor is the introduction of technologically advanced products, like low-maintenance dialysis equipment and artificial kidney. In March 2021, Baxter International Inc. announced the US Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. This indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.

Additionally, there is a higher prevalence rate for diabetes, which leads to cause end-stage renal disease in the long run, which may drive the market growth. According to the International Diabetes Federation, in 2019, around 463 million adults (20-79 years) were living with diabetes, and by 2045, it is expected to rise to 700 million. Diabetes is one of the leading causes of kidney failure, which is likely to drive the market studied over the forecast period.

However, the delay in diagnosing chronic kidney disease may restrain the market growth over the forecast period.

Scope of the Report

As per the scope of the report, end-stage renal failure, also known as an end-stage renal disease (ESRD), is the final, permanent stage of chronic kidney disease, where kidney function declines to the point that the kidneys can no longer function on their own.

The end-stage renal disease market is segmented by treatment (kidney transplantation and dialysis), diagnosis (blood test, urine test, imaging test, and other diagnoses), and geography (North America, Europe, Asia-Pacific, Middle East, Africa, and South America). The report offers the value (in USD million) for the above segments.

By Treatment
Kidney Transplantation
By Diagnosis
Blood Test
Urine Test
Imaging Test
Other Diagnoses
By Geography
North America
United States
United Kingdom
Rest of Europe
Asia Pacific
South Korea
Rest of Asia Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Dialysis Segment by Treatment is Expected to Witness a High Growth over the Forecast Period

Dialysis is a procedure that removes waste products from the blood, such as urea and creatinine, as a result of inadequate kidney function. It is frequently required for persons with chronic renal failure. The blood is cleansed, and extra fluid and toxins are eliminated during this operation.

Moreover, the demand for dialysis is expected to increase as the incidence of end-stage renal disease is tremendously increases, worldwide. The prevalence of end-stage renal disease (ESRD) is high and increasing at a significant rate. According to the US Renal Data System report of 2020, the number of patients with incident ESRD in 2018 was 131,636, an increase of 2.3% since 2017. Between 2017 and 2018, unadjusted ESRD incidence per million increased by 1.5%, while adjusted ESRD incidence per million increased by only 0.2%. The number of patients with incident ESRD who initiated in-center hemodialysis ranged from 111,000 to 113,000 for the fourth consecutive year in 2018. Meanwhile, the number of patients who initiated peritoneal dialysis and who received a preemptive transplant reached an all-time high of 18,631. Additionally, funding for dialysis is rising in the United States, according to the American Society of Nephrology.

The end-stage renal disease market is growing, as the population increases, globally, thus, raising funding for better dialysis products and services. For instance, on July 1, 2021, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule for Prospective Payment System (PPS) for renal dialysis services. Under the ESRD PPS for 2022, Medicare is expected to pay USD 8.9 billion to approximately 7,700 ESRD facilities for furnishing renal dialysis services.

On the other hand, high prevalence of diabetics, hypertension, rising incidences of kidney failures, lack of kidney donors for transplantation, tedious kidney transplant procedure, and increasing demand for home peritoneal dialysis treatment, thus, all factors put together to drive the segmental growth over the forecast period.

End Stage Renal Disease 2

Asia-Pacific is is Expected to Witness a High Growth over the Forecast Period

Asia Pacific is expected to witness high growth in end-stage renal disease due to the presence of high disposable income and the high acceptance rate of technologically improved products. Moreover, high blood pressure and diabetes cases in Asia Pacific may contribute to the market growth. According to the Asian Diabetics Prevention Initiatives, in 2020, 60% of the diabetic population in the world live in Asia. With a higher contribution of China and India, which is 113.9 million and 65.1 million adults with diabetes in China and India respectively, and by 2030, both China and India combined may have almost half a billion diabetic patients.

Additionally, growing patient affordability, aging population, lifestyle stress, a broad population base, improving diagnosis quality may fuel the market growth. According to a report published by the national health portal of the Indian Government estimates that every year about 2.2 lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 crore dialysis every year. Approximately 4,950 dialysis centers were available, largely in the private sector in India. The presence of a large number of dialysis centers in this region and a rise in the number of patients with chronic renal and kidney diseases are expected to boost the market growth.

End Stage Renal Disease Market2

Competitive Landscape

The market studied is a fragmented market owing to the presence of many major market players. Market players adopt the strategies, such as organic growth strategies (treatment type launches, treatment type approvals) and others (such as patents and events), which are being prioritized by corporations with inorganic growth strategies, like acquisitions, partnerships, and collaborations. Some of the market players are Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Medtronic PLC, B Braun Melsungen AG, Asahi Kasei Medical Co. Ltd, Cantel Medical, Nikkiso Co., etc.

Recent Developments

In June 2021, Baxter launched the Sharesource Analytics 1.0 Digital Health Module to enhance the clinical management of home dialysis patients.

In December 2020, Medtronic PLC announced the commercial launch of the Carpediem Cardio-Renal Pediatric Dialysis Emergency Machine in the United States.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase Number of Patient Suffering from Chronic Kidney Disease

      2. 4.2.2 Introduction of Technologically Advanced Products

      3. 4.2.3 Rising Prevalence of Diabetes and Hypertension

    3. 4.3 Market Restraints

      1. 4.3.1 Delay in Diagnosis of the Chronic Kidney Disease

    4. 4.4 INdustry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment

      1. 5.1.1 Kidney Transplantation

      2. 5.1.2 Dialysis

    2. 5.2 By Diagnosis

      1. 5.2.1 Blood Test

      2. 5.2.2 Urine Test

      3. 5.2.3 Imaging Test

      4. 5.2.4 Other Diagnoses

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Nipro Corporation

      2. 6.1.2 Fresenius SE & Co. KGaA

      3. 6.1.3 Baxter International Inc.

      4. 6.1.4 Medtronic PLC

      5. 6.1.5 B Braun Melsungen AG

      6. 6.1.6 Asahi Kasei Medical Co. Ltd

      7. 6.1.7 Cantel Medical

      8. 6.1.8 Nikkiso Co. Ltd

      9. 6.1.9 Becton, Dickinson and Co.

      10. 6.1.10 JCB Co. Ltd

    2. *List Not Exhaustive

**Competitive Landscape covers - Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global End-stage Renal Disease Market market is studied from 2018 - 2025.

The Global End-stage Renal Disease Market is growing at a CAGR of 10% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Nipro Corporation , Fresenius SE & Co. KGaA, Baxter International Inc, Medtronic PLC, B Braun Melsungen AG are the major companies operating in Global End-stage Renal Disease Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!